$MYGN News

Myriad Genetics (MYGN) Stock Sees Fair Value Lift After Split Analyst Revisions

Myriad Genetics Releases New MONSTAR-SCREEN-3 Data Demonstrating the Potential of Ultra-Sensitive MRD Detection in Colorectal and Pancreatic Cancers

Labcorp to buy Myriad’s prenatal health testing unit for $210M

Myriad Genetics (MYGN) Stock Trades Up, Here Is Why

Myriad Genetics Offloads Struggling Prenatal Unit for $210 Million to Labcorp

Myriad Genetics and Labcorp Announce Definitive Agreement for Myriad to Sell Prenatal Health Testing Business to Labcorp

Myriad Genetics To Sell Its Prenatal Health Testing Business, Including Prequel, Foresight, SneakPeek And FirstGene Tests, To Labcorp For $210M In Cash Plus Inventory Value

Myriad Genetics to Release Third Quarter 2026 Financial Results on November 4, 2026

What Myriad Genetics Doubters Saw Before The Drop

TD Cowen Maintains Hold on Myriad Genetics, Raises Price Target to $4.5

SOPHiA GENETICS and Myriad Genetics Announce New Collaboration to Advance Prostate Genomic Instability Score Technology

SOPHiA GENETICS and Myriad Genetics Announce New Collaboration to Advance Prostate Genomic Instability Score Technology

Myriad Genetics and SOPHiA GENETICS Announce New Collaboration to Advance Prostate Genomic Instability Score Technology

SOPHiA GENETICS, Myriad Genetics Collaborate To Advance New Prostate Cancer-specific Genomic Instability Score Technology

Myriad Genetics (MYGN) Stock Sees Fair Value Lift As Analysts Weigh Split Targets

Why Is Myriad Genetics (MYGN) Stock Soaring Today

Craig-Hallum Maintains Buy on Myriad Genetics, Raises Price Target to $8

3 Reasons MYGN is Risky and 1 Stock to Buy Instead

Myriad Genetics (MYGN) Stock Fair Value Moves Lower After Analyst Cuts And Guidance Reset

Myriad Genetics Appoints Vishal Sikri Executive Vice President - Commercial